By ,
Published October 27, 2015
The U.S. Food and Drug Administration on Monday approved Alkermes Plc's longer-acting injectable version of blockbuster schizophrenia pill Abilify, making the treatment available in two doses.
Abilify, developed by Japanese drugmaker Otsuka Pharmaceuticals and sold in the United States by Bristol-Myers Squibb Co, is already facing generic competition.
Alkermes' injectable version, Aristada, is expected to be launched immediately, the company said in a statement on Monday.
https://www.foxnews.com/health/alkermes-schizophrenia-drug-aristada-gets-fda-nod